Vaccines & Disease · Measles

Measles Disease & Vaccine Information

Below are brief introductions to measles disease and the measles vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.

The Disease

Measles: The Disease

Measles (rubeola) is a highly contagious respiratory disease spread by coughing, sneezing, or simply being in close contact with an infected individual. The disease can be spread even when the rash is not visible.1 Measles tends to be more severe in children under five and adults over 20.2 Initial measles symptoms include fever, cough, runny nose, red irritated eyes, and sore throat with tiny white spots on the cheeks inside the mouth (Koplik spots). These symptoms generally last 2-4 days and are followed by the signature itchy red rash on the body around the fourth or fifth day.

Most measles cases in the U.S. resolve without complication, though serious complications can occur.3 According to the U.S. Centers for Disease Control (CDC), Americans born before 1957 have naturally-acquired immunity to measles through past exposure to the illness.4 Infants born to mothers with naturally-acquired antibodies to measles benefit from passive maternal immunity. There is also evidence that mothers who have recovered from measles pass short-term measles immunity to their infants by breastfeeding.5

Download NVIC’s special report on eradicating measles (PDF)

The Vaccine

Measles Vaccine

The measles vaccine is a weakened (attenuated) form of the live measles virus. There are three live virus vaccines currently available for use in the U.S.: Merck’s MMRII vaccine containing measles, mumps, and rubella attenuated live viruses;6 Merck’s Proquad (MMRV) vaccine containing measles, mumps, rubella, and varicella attenuated live viruses;7 and GlaxoSmithKline’s PRIORIX containing measles, mumps, and rubella attenuated live viruses.8 The CDC currently recommends that children receive two doses of a measles containing vaccine, with the first dose administered between 12-15 months and the second dose between 4-6 years.9 The CDC also recommends that individuals born after 1957 who have no laboratory evidence of immunity or documentation of vaccination should receive at least one dose of MMR vaccine.10

Quick Facts

Measles at a glance

Measles Quick Facts

  1. After coming in contact with someone infected with measles, the incubation period to onset of the rash is between 7 and 21 days, with an average of 14 days. The period leading up to the appearance of the rash is characterized by a rising fever that peaks at 103-105 degrees F.11
  2. Three years before the first measles vaccine became available in 1960, there were approximately 442,000 reported measles cases and 380 related deaths in the U.S.1213 among the 3.5 to 5 million Americans likely infected with measles.1415 Measles-associated deaths are rare in the U.S., with the last reported death occurring in 2015.16

Measles Vaccine Quick Facts

  1. There are three measles vaccines currently in use in the United States. Two vaccines, MMRII17 and PRIORIX,18 are combination measles-mumps-rubella (MMR) live virus vaccines. The third, ProQuad, is a combination measles-mumps-rubella-varicella (MMR-V) live virus vaccine.19 Both MMRII and ProQuad are manufactured and distributed by Merck, while PRIORIX is manufactured and distributed by GlaxoSmithKline (GSK).20 The CDC recommends children receive the first dose of MMR vaccine between 12 and 15 months and the second dose between 4 and 6 years.21
  2. As of January 2, 2026, there have been 118,645 reports of measles-vaccine reactions, hospitalizations, injuries, and deaths following measles vaccinations made to the federal Vaccine Adverse Events Reporting System (VAERS), including 580 related deaths, 9,203 hospitalizations, and 2,251 related disabilities. Approximately 50 percent of those adverse events occurred in children under three years old.
References
  1. 1US Centers for Disease Control and Prevention. Nov. 5, 2020.
  2. 2US Centers for Disease Control and Prevention. Measles Transmission. Nov. 5, 2020.
  3. 3Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Measles. 13th ed. Centers for Disease Control (CDC) Aug. 18, 2021.
  4. 4US Centers for Disease Control and Prevention. Evidence of Immunity. Nov. 5, 2020.
  5. 5Adu FD, Adeniji JA. Measles Antibodies in the Breast Milk of Nursing Mothers. Afr J Med Med Sci. Dec 1995; 24(4):385-8.
  6. 6Merck, Sharp & Dohme Corp. Package Insert – Measles, Mumps and Rubella Virus Vaccine, Live. U.S. Food and Drug Administration Dec. 14, 2020.
  7. 7Merck Sharpe & Dohme Corp. Package Insert – Refrigerator-Stable Formulation – ProQuad. U.S. Food and Drug Administration Apr. 16, 2021.
  8. 8GlaxoSmithKline. PRIORIX. U.S. Food and Drug Administration July 1, 2022.
  9. 9McLean HQ. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Jun. 14, 2013.
  10. 10McLean HQ. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Jun. 14, 2013.
  11. 11Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Measles. 13th ed. Centers for Disease Control (CDC) Aug. 18, 2021.
  12. 12Public Health Service. Reported incidence of notifiable diseases in the United States 1962. MMWR 1963; 11(53): 1-29.
  13. 13National Center for Health Statistics. Death Rates for Selected Causes by 10-Year Age Groups, Race, and Sex: Death Registration States, 1900-32, and United States, 1933-98. National Vital Statistics System. Nov. 6, 2015.
  14. 14US Centers for Disease Control and Prevention. Measles, Mumps and Rubella – Vaccine Use and Strategies for Elimination of Measles, Rubella and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR May 22, 1998.
  15. 15Wood DJ, Brunell PA. Measles Control in the United States: Problems of the Past and Challenges for the Future. Clin Microbiol Rev Apr. 1995; 8(2): 260-267.
  16. 16Adams DA, Thomas KR, Jajosky RA, et al. Summary of Notifiable Infectious Diseases and Conditions — United States, 2015. MMWR Aug. 11, 2017; 64(53):1–143.
  17. 17Merck, Sharp & Dohme Corp. Package Insert – Measles, Mumps and Rubella Virus Vaccine, Live. U.S. Food and Drug Administration Dec. 14, 2020.
  18. 18GlaxoSmithKline. PRIORIX. July 1, 2022.
  19. 19Merck Sharpe & Dohme Corp. Package Insert – Refrigerator-Stable Formulation – ProQuad. U.S. Food and Drug Administration Apr. 16, 2021.
  20. 20US Food and Drug Administration. Vaccines Licensed for Use in the United States. July 5, 2022.
  21. 21McLean HQ. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Jun. 14, 2013.
Select disease / vaccine